The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2016 | ASCO 2016 highlights for CLL
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX discusses his highlights for chronic lymphocytic leukemia (CLL) from the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL. Prof. Wierda mentions the update on venetoclax in patients who have relapsed or are intolerant to ibrutinib or idelalisib, the idelalisib plus ofatumumab as well as the bendamustine plus rituximab and idelalisib randomized trials.
